An interventional study of Esketamine, dexmedetomidine, pregabalin and Sufentanil in Acute and Chronic Postsurgical Pain, sponsored by Beijing Tiantan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Pain, Postoperative by Beijing Tiantan Hospital — 8 open to participants now, 9 under way, 1 of them phase 3. Pain, Postoperative · Beijing Tiantan Hospital.
Among the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital, this one is the 15th largest by planned enrollment, is one of 6 that started in 2026, is one of 11 with no phase, and was the 25th registered.
5,648 studies on the registry are indexed under Pain, Postoperative; 1,229 are open to participants now.
Browse Pain, Postoperative studies →8 of the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–64
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Beijing Tiantan Hospital · Sites in China
Ages 2–12
Beijing Tiantan Hospital
Ages 18–64
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 241 (36%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 13
First in 2019; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 132 is above the median of 75 across 4,825 interventional studies indexed under Pain, Postoperative.
Median enrollment 136 across the 28 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 491 studies on the registry; 295 are open to participants now.
3 of the studies in Pain, Postoperative by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06406829Beijing Tiantan HospitalPerioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy | 2026-12-31 |
| NCT07591233Beijing Tiantan HospitalPre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Laparoscopic Surgery | 2027-03-10 |
| NCT07341854Beijing Tiantan HospitalDexamethasone Palmitate for Postoperative Pain | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic pain is one of the common postoperative complications in major surgery patients, which seriously affects the prognosis of patients. The postoperative pain level in spinal cord surgery patients is severe, and the incidence of CPSP can be as high as 40%.
Prolonged multimodal analgesia strategies using non-opioid or low-opioid receptor agonists can safely extend the postoperative pain window to one month, thereby further avoiding the occurrence of chronic postoperative pain.
This study provides guidance for perioperative pain management strategies in spinal surgery patients and further improves their long-term prognosis and outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pre-operative (1 hour): pregabalin 150mg; Intraoperative: Esketamine 0.09 mg/kg/h pumping; Post-operative: Esketamine combined with dexmedetomidine PCA: the esketamine dosage is 0.06 mg/kg/h, dexmedetomidine dosage is 1.5 μg/kg, and the PCA pump is used for 48 hours; Pregabalin 75 mg bid in 1-7 days and Pregabalin 75 mg qd in 8-21days. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail. drugs:Esketamine, dexmedetomidine, pregabalin device:Patient Controlled Analgesia(PCA)
Drug: Esketamine, dexmedetomidine, pregabalin
The participant will be administrated by Sulfentanil PCA (1.5μg/kg) in postoperative 48h. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail.
Drug: Sufentanil
Pre-operative (1 hour): pregabalin 150mg; Intraoperative: Esketamine 0.09 mg/kg/h pumping; Post-operative: Esketamine combined with dexmedetomidine PCA: the esketamine dosage is 0.06 mg/kg/h, dexmedetomidine dosage is 1.5 μg/kg, and the PCA pump is used for 48 hours; Pregabalin 75 mg bid in 1-7 days and Pregabalin 75 mg qd in 8-21days. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail. drugs:Esketamine, dexmedetomidine, pregabalin device:Patient Controlled Analgesia(PCA)
Using sufentanil PCA pump for 48 h. The sufentanil dosage is 1.5μg/kg. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail. drugs:sufentanil device: Patient Controlled Analgesia(PCA)
Incidence of moderate-to-severe chronic pain at 3 months postoperatively
Time frame: postoperative 3 months
No study locations are listed for this record.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 2,094 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 13 months is above that.
Counting every sponsor, half of 2,107 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.